Sort by
Characterization of Inflammatory Bowel Disease in the Elderly According to Age of Onset
Manuel Bracho González,
Raúl Vicente Olmedo Martín,
Ana Isabel Morales Bermúdez,
Miguel Jiménez Pérez
Posted: 21 November 2024
Influenza Virus-Induced Acute Necrotizing Encephalopathy in Two Young Children
Prisca Largo,
Olivia C. Arnone,
Francesco Sacco,
Gaetano Cantalupo,
Paolo Biban
Posted: 21 November 2024
Exploring the Link between Interoception and Symptom Severity in Premature Ventricular Contractions
Alena S. Limonova,
Irina A. Minenko,
Anastasia A. Sukmanova,
Vladimir A. Kutsenko,
Sofya P. Kulikova,
Maria A. Nazarova,
Karapet Davtyan,
Oxana M. Drapkina,
Alexandra I. Ershova
Posted: 21 November 2024
Does Cryopreservation Negatively Affect Semen Parameters?Does Cryopreservation Negatively Affect Semen Parameters?
Anna Justyna Milewska,
Agnieszka Kuczyńska,
Michał Pawłowski,
Iwo Martynowicz,
Sebastian Deluga-Białowarczuk,
Piotr Sieczyński,
Waldemar Kuczyński,
Robert Milewski
Posted: 21 November 2024
Synergistic Potential of Antibiotics with Cancer Treatments
Giuseppe Nardo,
Pan Pantziarka,
Matteo Conti
Intratumoral microbiota, the diverse community of microorganisms residing within tumor tissues, represent an emerging and intriguing field in cancer biology. These microbial populations are distinct from the well-studied gut microbiota, offering novel insights into tumor biology, cancer progression, and potential therapeutic interventions. Recent studies have explored the use of certain antibiotics to modulate intratumoral microbiota and enhance the efficacy of cancer therapies, showing promising results. Antibiotics can alter intratumoral microbiota’s composition, which may have a major role in promoting cancer progression and immune evasion. Certain bacteria within tumors can promote immunosuppression and resistance to therapies. By targeting these bacteria, antibiotics can help create a more favorable environment for chemotherapy, targeted therapy and immunotherapy to act effectively. Some bacteria within the tumor microenvironment produce immunosuppressive molecules that inhibit the activity of immune cells. The combination of antibiotics and other cancer therapies holds significant promise for creating a synergistic effect and enhancing the immune response against cancer. In this review we analyze several preclinical studies that have been conducted to demonstrate the synergy between antibiotics and other cancer therapies and discuss possible clinical implications.
Intratumoral microbiota, the diverse community of microorganisms residing within tumor tissues, represent an emerging and intriguing field in cancer biology. These microbial populations are distinct from the well-studied gut microbiota, offering novel insights into tumor biology, cancer progression, and potential therapeutic interventions. Recent studies have explored the use of certain antibiotics to modulate intratumoral microbiota and enhance the efficacy of cancer therapies, showing promising results. Antibiotics can alter intratumoral microbiota’s composition, which may have a major role in promoting cancer progression and immune evasion. Certain bacteria within tumors can promote immunosuppression and resistance to therapies. By targeting these bacteria, antibiotics can help create a more favorable environment for chemotherapy, targeted therapy and immunotherapy to act effectively. Some bacteria within the tumor microenvironment produce immunosuppressive molecules that inhibit the activity of immune cells. The combination of antibiotics and other cancer therapies holds significant promise for creating a synergistic effect and enhancing the immune response against cancer. In this review we analyze several preclinical studies that have been conducted to demonstrate the synergy between antibiotics and other cancer therapies and discuss possible clinical implications.
Posted: 21 November 2024
Diabetes Mellitus: A Risk Factor in Schlemm’s Canal-Based MIGS
Etsuo Chihara,
Eri Nakano,
Tomoyuki Chihara
Objectives: To evaluate the impact of diabetes mellitus (DM) on the outcome of Schlemm’s canal based minimally invasive glaucoma surgery (MIGS). Methods: In a retrospective interventional cohort study, post- operative intraocular pressure (IOP) and intracameral bleeding were analyzed in 25 diabetic and 84 non-diabetic patients with primary open angle glaucoma (POAG) or ocular hypertension (OH). Results: The mean follow-up period for all 109 eyes was 35.3±24.8 months. There was no significant difference in pre-operative IOP between diabetic and non-diabetic cohorts. However, the post-surgical IOP between 3 months and 2 years was significantly higher in the diabetic cohort (P=0.019 to 0.001). The 3-year survival probability of achieving an IOP≦15 mmHg was 17.8±0.09% in diabetic patients, significantly lower than the 30.4±0.06% observed in non- diabetic patients (P=0.042 Log-rank test). The 3-year survival probability of achieving an IOP≦18 mmHg was 56.7±0.12% in diabetic patients compared to 79.5±0.05% in non-diabetic patients, indicating a marginally significant difference between diabetic and non-diabetic cohorts (P=0.065). When the random effect of diabetes mellitus (DM) was analyzed alongside the fixed effects of preoperative IOP, age, refractive error and extent of canal opening using a multivariate linear mixed model, DM emerged as a significant risk factor for higher postoperative IOP at both 6 and 12 months (P<0.001). Conclusions: Diabetes mellitus is a significant risk factor for poor outcomes following Schlemm’s canal based MIGS, particularly in achieving lower postoperative IOP.
Objectives: To evaluate the impact of diabetes mellitus (DM) on the outcome of Schlemm’s canal based minimally invasive glaucoma surgery (MIGS). Methods: In a retrospective interventional cohort study, post- operative intraocular pressure (IOP) and intracameral bleeding were analyzed in 25 diabetic and 84 non-diabetic patients with primary open angle glaucoma (POAG) or ocular hypertension (OH). Results: The mean follow-up period for all 109 eyes was 35.3±24.8 months. There was no significant difference in pre-operative IOP between diabetic and non-diabetic cohorts. However, the post-surgical IOP between 3 months and 2 years was significantly higher in the diabetic cohort (P=0.019 to 0.001). The 3-year survival probability of achieving an IOP≦15 mmHg was 17.8±0.09% in diabetic patients, significantly lower than the 30.4±0.06% observed in non- diabetic patients (P=0.042 Log-rank test). The 3-year survival probability of achieving an IOP≦18 mmHg was 56.7±0.12% in diabetic patients compared to 79.5±0.05% in non-diabetic patients, indicating a marginally significant difference between diabetic and non-diabetic cohorts (P=0.065). When the random effect of diabetes mellitus (DM) was analyzed alongside the fixed effects of preoperative IOP, age, refractive error and extent of canal opening using a multivariate linear mixed model, DM emerged as a significant risk factor for higher postoperative IOP at both 6 and 12 months (P<0.001). Conclusions: Diabetes mellitus is a significant risk factor for poor outcomes following Schlemm’s canal based MIGS, particularly in achieving lower postoperative IOP.
Posted: 21 November 2024
Differential Diagnosis and Rapid Clinical Resolution of a Neurological Case of Feline Infectious Peritonitis (FIP) Using GS441528
Huong (Amy) Huynh,
Pamela Moraguez,
Logan M Watkins,
Jonathan H. Wood,
Ximena A Olarte-Castillo,
Gary R. Whittaker
Posted: 21 November 2024
Medical Costs and Economic Impact of Hyperkalemia in a Cohort of Heart Failure Patients with Reduced Ejection Fraction
Andrea Lopez-López,
Margarita Regueiro-Abel,
Emilio Paredes-Galan,
Charigan Abou Johk-Casas,
Jose Maria Vietez-Florez,
Juliana Elices-Teja,
Jorge Armesto-Rivas,
Raúl Franco-Gutiérrez,
Ramón Rios-Vazquez,
Carlos González-Juanatey
Posted: 21 November 2024
Breed-associated Differences in Differential Gene Expression Following Immunotherapy-Based Treatment of Canine High-Grade Glioma
Susan A Arnold,
Walter C Low,
G. Elizabeth Pluhar
Posted: 21 November 2024
A One Health Perspective on the Resurgence of Flea-Borne Typhus in Texas in the 21st Century. Part 1. The Bacteria, The Cat Flea, Urbanization, and Climate Change
Gregory M Anstead
Posted: 21 November 2024
of 1,351